Regorafenib Combined with Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

I'm Interested!

Please call
1-800-641-2422

Efficacy of Oral Regorafenib Combined with Intra-Muscular Injection of Fulvestrant in Patients with Recurrent Low-Grade Serious Ovarian Cancer: A Phase II Single Arm Trial

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Ovarian

Study Purpose

To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.

Principal Investigator
Sarah Lynam MD

Department/Division
Cancer (Gynecological)

Locations

UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: STUDY20210199
StudyID: CASE2820
ClinicalTrials.gov: NCT05113368

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422